ABVC BioPharma (ABVC) Competitors $1.06 +0.03 (+2.91%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. IKNA, MDCX, DTIL, BYSI, MIST, FBLG, RPTX, BDRX, ONCY, and PEPGShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Ikena Oncology (IKNA), Medicus Pharma (MDCX), Precision BioSciences (DTIL), BeyondSpring (BYSI), Milestone Pharmaceuticals (MIST), FibroBiologics (FBLG), Repare Therapeutics (RPTX), Biodexa Pharmaceuticals (BDRX), Oncolytics Biotech (ONCY), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Ikena Oncology Medicus Pharma Precision BioSciences BeyondSpring Milestone Pharmaceuticals FibroBiologics Repare Therapeutics Biodexa Pharmaceuticals Oncolytics Biotech PepGen ABVC BioPharma (NASDAQ:ABVC) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking. Do insiders & institutionals have more ownership in ABVC or IKNA? 11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 11.9% of ABVC BioPharma shares are owned by insiders. Comparatively, 5.9% of Ikena Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor ABVC or IKNA? Ikena Oncology received 30 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformABVC BioPharmaN/AN/AIkena OncologyOutperform Votes3058.82% Underperform Votes2141.18% Is ABVC or IKNA more profitable? Ikena Oncology has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. Ikena Oncology's return on equity of -36.88% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharma-1,619.65% -104.94% -56.81% Ikena Oncology N/A -36.88%-33.08% Which has more risk & volatility, ABVC or IKNA? ABVC BioPharma has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Does the media favor ABVC or IKNA? In the previous week, ABVC BioPharma had 1 more articles in the media than Ikena Oncology. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.89 beat ABVC BioPharma's score of 1.87 indicating that Ikena Oncology is being referred to more favorably in the news media. Company Overall Sentiment ABVC BioPharma Very Positive Ikena Oncology Very Positive Do analysts rate ABVC or IKNA? Ikena Oncology has a consensus price target of $3.00, suggesting a potential upside of 136.22%. Given Ikena Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Ikena Oncology is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better earnings and valuation, ABVC or IKNA? ABVC BioPharma has higher earnings, but lower revenue than Ikena Oncology. ABVC BioPharma is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$509.59K32.82-$10.52M-$0.47-2.26Ikena Oncology$659K93.00-$68.17M-$1.01-1.26 SummaryIkena Oncology beats ABVC BioPharma on 13 of the 17 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.73M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.237.4422.4418.48Price / Sales32.82242.70393.95103.59Price / CashN/A65.8538.1834.62Price / Book1.046.516.774.25Net Income-$10.52M$143.21M$3.22B$248.23M7 Day Performance16.36%1.98%1.45%0.89%1 Month Performance-19.70%6.89%3.96%3.53%1 Year Performance-6.19%-2.52%16.07%5.08% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma1.0933 of 5 stars$1.06+2.9%N/A-15.2%$16.73M$509,589.00-1.2330Earnings ReportPositive NewsIKNAIkena Oncology2.7431 of 5 stars$1.14+2.7%$3.00+163.2%-3.8%$55.01M$659,000.00-0.9370Positive NewsMDCXMedicus PharmaN/A$4.06+1.5%$12.00+195.6%N/A$54.47MN/A0.00N/AAnalyst ForecastNews CoverageGap UpDTILPrecision BioSciences4.2753 of 5 stars$5.13+2.2%$37.67+634.2%-45.8%$54.12M$68.70M85.51200Positive NewsBYSIBeyondSpringN/A$1.34+2.3%N/A-13.4%$54.02M$1.88M0.0080Positive NewsGap UpMISTMilestone Pharmaceuticals1.8804 of 5 stars$1.01+13.6%$17.00+1,583.2%-20.0%$53.89M$1M-1.2530News CoveragePositive NewsGap UpHigh Trading VolumeFBLGFibroBiologics2.6698 of 5 stars$1.38+16.0%$13.00+842.0%-88.1%$52.07MN/A-4.0610Short Interest ↓Gap UpRPTXRepare Therapeutics3.3579 of 5 stars$1.20flat$4.50+275.0%-55.8%$51.01M$53.48M-0.60180Upcoming EarningsBDRXBiodexa Pharmaceuticals0.4316 of 5 stars$1.38-3.5%N/AN/A$50.43M$83,000.000.0020ONCYOncolytics Biotech1.5529 of 5 stars$0.58+2.5%$4.33+653.6%-48.6%$49.69MN/A-2.1330Upcoming EarningsPEPGPepGen2.9105 of 5 stars$1.52+14.3%$10.33+579.8%-87.2%$49.69MN/A-0.5130 Related Companies and Tools Related Companies Ikena Oncology Competitors Medicus Pharma Competitors Precision BioSciences Competitors BeyondSpring Competitors Milestone Pharmaceuticals Competitors FibroBiologics Competitors Repare Therapeutics Competitors Biodexa Pharmaceuticals Competitors Oncolytics Biotech Competitors PepGen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABVC Stock Free ABVC Stock Alerts